Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BBT 401

Next Previous
X
Search
Drug Profile

BBT 401

Alternative Names: BBT 401; BBT-401-1S; DWP-305401

Latest Information Update: 28 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Korea Research Institute of Chemical Technology; Sungkyunkwan University
  • Developer Bridge Biotherapeutics
  • Class Anti-inflammatories; Eye disorder therapies; Neuroprotectants; Peptides; Small molecules
  • Mechanism of Action Ubiquitin protein ligase complex inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Ulcerative colitis
  • Discontinued Age-related macular degeneration; Multiple sclerosis

Most Recent Events

  • 28 Nov 2023 No recent reports of development identified for phase-I development in Ulcerative-colitis in New Zealand (Rectal)
  • 20 Feb 2023 Efficacy data and adverse events data from a phase IIa trial in Ulcerative Colitis released by Bridge Biotherapeutics
  • 12 Jul 2022 Bridge Biotherapeutics in collaboration with Covance completes a phase II trial in Ulcerative colitis in New Zealand, Poland, South Korea, Ukraine and USA (PO) (NCT04596293)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top